The American Academy of Neurology has reported promising results in early trials of the drug, Epidiolex, which is 98 percent pure cannabidiol, in treating severe forms of pediatric epilepsy, including Dravet syndrome and Lennox-Gastaut syndrome.
Tag Archives: GW Pharma
Cannabis stocks were mostly lower today, not too surprising given the day of the week. Unfortunately, the earlier enthusiasm around the potentially game changing CARERS Act has quickly waned.
Volumes in the cannabis space were nonexistent. Not surprising given the general trend of Fridays and the day before a long weekend.
This morning’s November ADP jobs report came in with more than 200,000 jobs added. The U.S. economy continues to chug along, but this report was a bit softer than expected.
The S&P 500, Russell 2k and Russell MicroCap all experienced gains of > 1.7%. MJIC Marijuana Index and Benzinga 420 Marijuana Index both underperformed, with a gain of 0.09% and a decline of 1.51% respectively.
LONDON, Oct 8 (Reuters) – A pioneering cannabis drug developed by British firm GW Pharmaceuticals for treating spasticity in multiple sclerosis has been rejected as not cost-effective in the company’s home market.
Given the title of yesterday’s Market Musings piece and the subject of today’s, you, dear reader, could be forgiven for thinking that I have some kind of a drug problem. I can assure you that I don’t. I just have a problem with some drug stocks, both the non-conventional and more traditional.
GW Pharma utilizies CBD technology in order to develop a new breakthrough treatment for pediatric epilepsy.